Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 5/20 | 0.54 |
| ▸ | HTR1B | P28222 | 5/20 | 0.54 |
| ▸ | GHSR | Q92847 | 10/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604349 | 1.00 | HTR1D (0.54) | HTR1DHTR1BGHSRLCKWEE1 | |
| SCHEMBL6603712 | 0.92 | GHSR (0.46) | HTR1DHTR1BGHSRLCKWEE1 | |
| SCHEMBL6603709 | 0.92 | GHSR (0.46) | HTR1DHTR1BGHSRLCKWEE1 | |
| SCHEMBL6604750 | 0.80 | HTR1B (0.81) | HTR1DHTR1BGHSRHTR1A | |
| SCHEMBL6604757 | 0.80 | HTR1B (0.81) | HTR1DHTR1BGHSRHTR1A | |
| SCHEMBL6606340 | 0.79 | HTR1B (0.67) | HTR1DHTR1BGHSRHTR1A | |
| SCHEMBL6606338 | 0.79 | HTR1B (0.67) | HTR1DHTR1BGHSRHTR1A | |
| SCHEMBL6605304 | 0.72 | HTR1B (0.69) | HTR1DHTR1BGHSRHTR1A | |
| SCHEMBL6605279 | 0.72 | HTR1B (0.69) | HTR1DHTR1BGHSRHTR1A | |
| SCHEMBL6603215 | 0.70 | HTR1B (1.00) | HTR1DHTR1BGHSRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM P.I.C. | 2004-09-09 | — | — | US | claimed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | claimed |
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM P.I.C. | 2004-09-09 | — | — | US | disclosed |
| US-6747030-B1 | CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | disclosed |
| EP-1216239-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023374-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | HTR1B, HTR2B, HTR2A | HTR1D 8/4885HTR1B 1/4885GHSR 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.